DHEA — Dehydroepiandrosterone <table class="infobox infobox-therapeutic">
...
DHEA — Dehydroepiandrosterone <table class="infobox infobox-therapeutic">
Path: /therapeutics/dhea
Also Known As: Dehydroepiandrosterone, DHEA-S (sulfate form), Androstenolone
Chemical Formula: C_19H_28O_2
Molecular Weight: ~288 Da (DHEA), ~372 Da (DHEA-S)
Class: Endogenous androgen/preandrogen
Overview
Mermaid diagram (expand to render)
DHEA is the most abundant circulating steroid hormone in humans, produced primarily by the adrenal cortex. It serves as a precursor to both androgen and estrogen hormones and has direct biological effects on multiple organ systems including the brain. DHEA levels decline dramatically with age — by approximately 80% between ages 25 and 75 — which has led to interest in supplementation for age-related conditions including neurodegeneration.
Mechanism of Action
1. Neuroprotective Effects
Anti-apoptotic signaling : DHEA activates pro-survival pathways including PI3K/Akt and MAPK/ERK[@manolopoulos2015]Anti-glutamatergic effects : Reduces NMDA receptor-mediated excitotoxicity[@woolf2006]BDNF modulation : Increases brain-derived neurotrophic factor expression[@prasad2012]Amyloid interaction : Some evidence suggests direct binding to amyloid-β, reducing its toxicity[@aron2019]2. Anti-Inflammatory Properties
NF-κB inhibition : Suppresses nuclear factor kappa-B inflammatory pathway[@du2019]Cytokine reduction : Decreases pro-inflammatory TNF-α, IL-1β, IL-6[@morales2000]Microglial modulation : Shifts microglia toward anti-inflammatory (M2) phenotype[@ridet2001]3. Antioxidant Activity
Direct antioxidant : Scavenges free radicals[@olatunji2015]Enzyme upregulation : Increases glutathione peroxidase and SOD[@svec2000]Mitochondrial protection : Preserves mitochondrial function under stress[@charalampopoulos2008]4. Hormonal Effects
Androgen precursor : Converts to testosterone and dihydrotestosterone[@labrie1997]Estrogen precursor : Can convert to estrone and estradiol in peripheral tissues[@simpson2003]Neurosteroid effects : Modulates GABA-A and NMDA receptors directly[@majewska1995]Insulin sensitivity : Improves glucose metabolism in some studies[@patel2018]Lipid modulation : May improve lipid profiles[@valenti2019]Body composition : Associated with lean muscle mass maintenance[@tann2006]Evidence in Neurodegenerative Disease
Alzheimer's Disease
Parkinson's Disease
Preclinical Studies
Amyloid models : DHEA reduced amyloid burden and improved cognition in APP/PS1 mice[@wang2017]PD models : Protected dopaminergic neurons in MPTP models[@gonzalez2015]Tau models : Reduced tau phosphorylation in cell models[@li2018]Dosing and Administration
Typical Dosing Protocols
Administration Considerations
Timing : Morning administration preferred (mimics circadian rhythm)Cycling : Some protocols use 5 days on, 2 days offDHEA-S : More stable form; longer half-lifeMonitoring : Check DHEA-S serum levels periodicallyDuration : Effects may take 4-8 weeks to appearTarget Serum Levels
Young adult range : 200-300 µg/dL DHEA-S (morning)Therapeutic target : 150-250 µg/dL (age-adjusted)Optimal : Individualize based on symptoms and labsSafety Profile
Adverse Effects
Generally well-tolerated at doses ≤ 100 mg/day
Common : Acne, oily skin, mild hair loss (androgenic effects)Less common : Mood changes, insomnia, headacheRare : Liver enzyme elevation, cardiovascular effectsContraindications
Hormone-sensitive cancers (breast, prostate)
Active liver disease
Pregnancy/breastfeeding
Drug Interactions
Androgenic Concerns At higher doses, DHEA can convert to androgenic hormones:
Testosterone elevation : May increase DHT in prostate-sensitive tissueEstrogen conversion : May increase estrogen in peripheral tissuesMonitoring : Check hormone panels periodicallyRelevance to CBS/PSP Patient
Potential Benefits
Neuroprotection : Multiple mechanisms relevant to tauopathyAnti-inflammatory : Addresses neuroinflammation in CBS/PSPMood support : May help with depression/anxiety in chronic illnessEnergy : Addresses age-related decline in anabolic hormonesCognitive support : Some evidence for cognitive benefit
Case For
Multiple neuroprotective mechanisms relevant to tauopathy
Addresses age-related hormone decline
Relatively well-tolerated at moderate doses
Easily accessible as OTC supplement
Inexpensive compared to prescription therapies
Case Against
Limited large-scale clinical trial data in CBS/PSP
Variable individual response
Androgenic side effects possible
Not FDA-approved for neurodegeneration
Requires monitoring for hormone levels
Net Assessment Priority: Consider — DHEA supplementation may provide modest neuroprotective benefits with favorable safety profile at moderate doses (25-50 mg/day). The anti-inflammatory and neuroprotective mechanisms are relevant to tauopathy pathology. Recommend:
Baseline DHEA-S level testing
Start low (25 mg/day) and titrate based on levels
Monitor hormone panel (testosterone, estrogen) quarterly
Use if DHEA-S levels are below age-adjusted normal range
Confidence: Low-Moderate — Mechanistic rationale strong, mixed but generally positive clinical data, well-tolerated with monitoring.
Research Gaps and Future Directions
Tauopathy trials : No dedicated trials in CBS/PSPDosing optimization : Optimal dose for neuroprotection unclearBiomarker studies : Correlation between DHEA levels and disease markersCombination approaches : Synergy with other neuroprotective agents
Related Pages
[Testosterone](/mechanisms/testosterone-neurodegeneration-pathway) — Related hormone pathway
[Neuroinflammation](/mechanisms/neuroinflammation) — Related mechanism
[Neurotrophic factors](/therapeutics/bdnf-therapies) — Related approach
References
[Aron et al., J. Mol. Neurosci. (2019) (2019)](https://doi.org/10.1007/s12031-019-01323-5)
[Charalampopoulos et al., J. Neurosci. (2008) (2008)](https://doi.org/10.1523/JNEUROSCI.2008-08.02548)
[Du et al., J. Neuroinflammation (2019) (2019)](https://doi.org/10.1186/s12974-019-1543-z)
[Unknown, GRF2004 Study Group, Dement. Geriatr. Cogn. Disord. (2004) (2004)](https://doi.org/10.1159/000082068)
[Gonzalez et al., Neuropharmacology (2015) (2015)](https://doi.org/10.1016/j.neuropharm.2015.04.013)
[Kim et al., J. Clin. Neurol. (2019) (2019)](https://doi.org/10.3988/jcn.2019.15.1.44)
[Labrie et al., J. Steroid Biochem. Mol. Biol. (1997) (1997)](https://doi.org/10.1016/S0960-0760(97)
[Li et al., J. Steroid Biochem. Mol. Biol. (2018) (2018)](https://doi.org/10.1016/j.jsbmb.2018.03.012)
[Manolopoulos et al., J. Steroid Biochem. Mol. Biol. (2015) (2015)](https://doi.org/10.1016/j.jsbmb.2015.03.004)
[Morales et al., Endocrinology (2000) (2000)](https://doi.org/10.1210/endo.141.3.7363)
[Majewska et al., J. Neurosci. (1995) (1995)](https://doi.org/10.1523/JNEUROSCI.15-07-05240.1995)
[Nasrallah et al., J. Clin. Psychopharmacol. (2019) (2019)](https://doi.org/10.1097/JCP.0000000000001087)
Unknown, ClinicalTrials.gov NCT01715810 (n.d.)
[Olatunji et al., Steroids (2015) (2015)](https://doi.org/10.1016/j.steroids.2015.09.005)
[Prasad et al., J. Neurosci. Res. (2012) (2012)](https://doi.org/10.1002/jnr.23061)
[Patel et al., Diabetes Metab. Syndr. (2018) (2018)](https://doi.org/10.1016/j.dsx.2018.04.010)
[Ridet et al., Glia (2001) (2001)](https://doi.org/10.1002/glia.1105)
[Ravaglia et al., Neurology (2006) (2006)](https://doi.org/10.1212/01.wnl.0000194508.40017.4e)
[Svec et al., Endocr. Res. (2000) (2000)](https://doi.org/10.1080/07435800009036052)
[Simpson et al., Ann. Endocrinol. (2003) (2003)](https://doi.org/10.1016/S0003-4266(03)
[Sun et al., J. Neurol. Sci. (2016) (2016)](https://doi.org/10.1016/j.jns.2016.01.050)
[Tann et al., J. Clin. Endocrinol. Metab. (2006) (2006)](https://doi.org/10.1210/jc.2005-2142)
[Valenti et al., Aging Clin Exp Res. (2019) (2019)](https://doi.org/10.1007/s40520-019-01171-5)
[Woolf et al., Brain Res. (2006) (2006)](https://doi.org/10.1016/j.brainres.2006.02.107)
[Wang et al., J. Alzheimers Dis. (2017) (2017)](https://doi.org/10.3233/JAD-170279)
From the [SciDEX Exchange](/exchange) — scored by multi-agent debate
[Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — <span style="color:#81c784;font-weight:600">0.74</span> · Target: P2RY1 and P2RX7
[Mechanosensitive Ion Channel Reprogramming](/hypothesis/h-db6aa4b1) — <span style="color:#81c784;font-weight:600">0.65</span> · Target: PIEZO1 and KCNK2
[Lipid Droplet Dynamics as Phenotype Switches](/hypothesis/h-7d4a24d3) — <span style="color:#ffd54f;font-weight:600">0.57</span> · Target: DGAT1 and SOAT1
[Hippocampal CA3-CA1 circuit rescue via neurogenesis and synaptic preservation](/hypothesis/h-856feb98) — <span style="color:#81c784;font-weight:600">0.73</span> · Target: BDNF
[Vagal Afferent Microbial Signal Modulation](/hypothesis/h-ee1df336) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: GLP1R, BDNF
[Vocal Cord Neuroplasticity Stimulation](/hypothesis/h-e0183502) — <span style="color:#ffd54f;font-weight:600">0.48</span> · Target: CHR2/BDNF
Related Analyses:
[Astrocyte reactivity subtypes in neurodegeneration](/analysis/SDA-2026-04-01-gap-007) 🔄
[Circuit-level neural dynamics in neurodegeneration](/analysis/SDA-2026-04-02-26abc5e5f9f2) 🔄
[Digital biomarkers and AI-driven early detection of neurodegeneration](/analysis/SDA-2026-04-01-gap-012) 🔄
[What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's disease pathogenesi](/analysis/SDA-2026-04-01-gap-20260401-225155) 🔄
Show full description